Dramatic Antitumor Activity of Nivolumab in Advanced HER2-Positive Lung Cancer

Clin Lung Cancer. 2016 Sep;17(5):e179-e183. doi: 10.1016/j.cllc.2016.05.004. Epub 2016 Jun 4.

Authors

Chiara Catania¹, Antonio Passaro², Elena Guerini Rocco³, Gianluca Spitaleri², Massimo Barberis³, Cristina Noberasco², Ester Del Signore², Laura Travaini⁴, Filippo de Marinis²

Affiliations

¹ Thoracic Division, Medical Oncology Department, European Institute of Oncology, Milan, Italy. Electronic address: chiara.catania@ieo.it.
² Thoracic Division, Medical Oncology Department, European Institute of Oncology, Milan, Italy.
³ Division of Pathology, European Institute of Oncology, Milan, Italy.
⁴ Division of Nuclear Medicine, European Institute of Oncology, Milan, Italy.

PMID: 27349506
DOI: 10.1016/j.cllc.2016.05.004

No abstract available

Keywords: Activity of nivolumab; Anti-PDL1; ERBB family; Immunotherapy; Lung adenocarcinoma.

Publication types

Case Reports

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma of Lung
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
B7-H1 Antigen / metabolism
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lymphatic Metastasis
Middle Aged
Nivolumab
Positron Emission Tomography Computed Tomography
Receptor, ErbB-2 / genetics*

Substances

Antibodies, Monoclonal
Antineoplastic Agents
B7-H1 Antigen
CD274 protein, human
Nivolumab
ERBB2 protein, human
Receptor, ErbB-2